Menopause and Insulin Resistance: Testing and Treatment

Short answer: Insulin sensitivity declines through the menopause transition, driven by visceral fat accumulation and lean-mass loss rather than by ageing alone. Ask for HbA1c, fasting glucose, fasting insulin, a lipid panel, and ALT. Resistance training is the most efficient single intervention because skeletal muscle is the main site of glucose disposal; incretin therapy and metformin are the pharmacological options.

What to test

HbA1c and fasting glucose
Fasting insulin (for HOMA-IR)
Lipid panel including triglycerides and HDL
ALT, for hepatic steatosis
Blood pressure and waist circumference

Why muscle is the lever

Skeletal muscle disposes of the majority of post-meal glucose. Losing muscle through midlife shrinks that sink, and building it back enlarges it. Resistance training improves insulin sensitivity within weeks, independent of weight change.

← Back to menopause weight gain: causes and treatment

Want a plan that protects muscle rather than just cutting calories? A Kindr clinician will review your labs, body composition goals, sleep, and eligibility for medication together.

Start your visit →

Not ready? Ask Dot, our free AI menopause companion.

Frequently asked questions

Does hormone therapy improve insulin sensitivity?

Randomized data show a small favourable effect on glucose metabolism and a reduced incidence of new-onset diabetes, but hormone therapy is not prescribed for glycaemic control.

Is prediabetes reversible?

Frequently. The Diabetes Prevention Program showed a 58% reduction in progression to diabetes with intensive lifestyle change.

Menopause weight gain: causes and treatment

Mechanism, every treatment class, tools, evidence, and care. Start anywhere.

Pillar guide →Every option for midlife weight and metabolic change, ranked by the weight loss it produced in randomized trials — plus a metabolic-risk quiz, a time-to-result timeline, and an honest account of what hormone therapy does and does not do.Why menopause weight gain happens →Estradiol, visceral redistribution, lean-mass loss, and sleep — the mechanism in full.GLP-1 therapy in menopause →Semaglutide and tirzepatide: eligibility, trial effect sizes, side effects, muscle protection.Menopause belly fat →Visceral versus subcutaneous fat, why waist matters more than weight, and what shrinks it.Insulin resistance in menopause →Why glucose control worsens after the final period, what to test, and how to reverse it.Muscle, protein, and strength →Sarcopenia in midlife, protein targets, and how to train to keep lean mass.Diet patterns that work →Mediterranean, higher-protein, and time-restricted eating compared on real evidence.

Other Kindr symptom hubs

The brain fog hub →The menopause sleep hub →Peptide therapy: evidence, legality, and safety →The hot flashes hub →

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

Sources

Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022.
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023.
Greendale GA et al. Changes in body composition and weight during the menopause transition (SWAN). JCI Insight 2019.
Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002.
Estruch R et al. Primary prevention of cardiovascular disease with a Mediterranean diet (PREDIMED). N Engl J Med 2018.
The Menopause Society. 2022 Hormone Therapy Position Statement.

Educational content only — not a substitute for professional medical advice, diagnosis, or treatment. The severity quiz is a screening aid, not a diagnosis. Reviewed by the Kindr Health clinical team · Last reviewed 2026-07-26.